1. iPSC-derived hindbrain organoids to evaluate escitalopram oxalate treatment responses targeting neuropsychiatric symptoms in Alzheimer's disease.
- Author
-
Zivko C, Sagar R, Xydia A, Lopez-Montes A, Mintzer J, Rosenberg PB, Shade DM, Porsteinsson AP, Lyketsos CG, and Mahairaki V
- Subjects
- Humans, Serotonin metabolism, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear metabolism, Serotonergic Neurons drug effects, Serotonergic Neurons metabolism, Cell Differentiation drug effects, Male, Aged, Female, Selective Serotonin Reuptake Inhibitors pharmacology, Induced Pluripotent Stem Cells drug effects, Induced Pluripotent Stem Cells metabolism, Organoids drug effects, Organoids metabolism, Alzheimer Disease drug therapy, Alzheimer Disease metabolism, Rhombencephalon drug effects, Rhombencephalon metabolism, Citalopram pharmacology
- Abstract
Alzheimer's disease (AD) is the most common cause of dementia, and the gradual deterioration of brain function eventually leads to death. Almost all AD patients suffer from neuropsychiatric symptoms (NPS), the emergence of which correlates with dysfunctional serotonergic systems. Our aim is to generate hindbrain organoids containing serotonergic neurons using human induced Pluripotent Stem Cells (iPSCs). Work presented here is laying the groundwork for the application of hindbrain organoids to evaluate individual differences in disease progression, NPS development, and pharmacological treatment response. Human peripheral blood mononuclear cells (PBMCs) from healthy volunteers (n = 3), an AD patient without NPS (n = 1), and AD patients with NPS (n = 2) were reprogrammed into iPSCs and subsequently differentiated into hindbrain organoids. The presence of serotonergic neurons was confirmed by quantitative reverse transcription PCR, flow cytometry, immunocytochemistry, and detection of released serotonin (5-HT). We successfully reprogrammed PBMCs into 6 iPSC lines, and subsequently generated hindbrain organoids from 6 individuals to study inter-patient variability using a precision medicine approach. To assess patient-specific treatment effects, organoids were treated with different concentrations of escitalopram oxalate, commonly prescribed for NPS. Changes in 5-HT levels before and after treatment with escitalopram were dose-dependent and variable across patients. Organoids from different people responded differently to the application of escitalopram in vitro. We propose that this 3D platform might be effectively used for drug screening purposes to predict patients with NPS most likely to respond to treatment in vivo and to understand the heterogeneity of treatment responses., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF